Startups
Edit
Patients for Affordable Drugs
https://patientsforaffordabledrugs.org/Last activity: 22.05.2024
Active
Patients For Affordable Drugs is the only independent national patient organization focused exclusiv
Overview
Location
United States, District of Columbia, Washington
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 20, 2024 | Senate's new controversial patent reform target | figcaption>span]:font-sans"> Sens. Chris Coons and Thom Tillis are pushing a pair of bills that they say are essential to overhauling the patent process, including for drugs and genomics, but that critics contend could wind up he... |
| Oct 9, 2023 | Venture Capital Firm Shares Ambitious Value-Based Care Strategy: Buy a Health System | The opening day of the HLTH 2023 event offered a blockbuster announcement from General Catalyst CEO Hemant Taneja. Dr. Marc Harrison, the former CEO of Intermountain Healthcare who joined General Catalyst last year, will lead a new initiati... |
| Jan 14, 2021 | Drug companies keep raising prices | Sign up for our daily briefingMake your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes. Enter your email address Please enter a valid email. Please enter a valid email. Subscription failedSub... |
| Oct 17, 2017 | The cost of gene therapy for patients goes well beyond the drug’s price | Although Kymriah’s price tag has “shattered oncology drug pricing norms,” said Leonard Saltz, chief of gastrointestinal oncology at Memorial Sloan Kettering Cancer Center in New York, “the sticker price is just the starting point.” These th... |
| Aug 23, 2017 | Will a new leukemia drug from Novartis be a quantum leap for cancer drug prices? | “It’s going to cost a fortune,” said Dr. Ivan Borrello at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore. “From what we’re hearing, this will be a quantum leap more expensive than other cancer drugs,” said Leonard Salt... |
| Aug 18, 2017 | Preemptive shaming assault on Novartis’ CAR-T pioneer underscores a disconnect on R&D costs | It’s no secret that taxpayers fund a lot of the basic science work done in the US. But should that early research support for new drugs translate into lower prices? A group called Patients for Affordable Drugs thinks so, launc... |
| The cost of gene therapy for patients goes well beyond the drug’s price | Outrage over the high cost of cancer care has focused on skyrocketing drug prices, including the $475,000 price tag for the country’s first gene therapy, Novartis’ Kymriah, a leukemia treatment approved in August. But the total costs of Kym... | |
| Will a new leukemia drug from Novartis be a quantum leap for cancer drug prices? | When doctors talk about a new leukemia drug from Novartis, they ooze enthusiasm, using words like “breakthrough,” “revolutionary” and “a watershed moment.” But when they think about how much the therapy is likely to cost, their tone turns a... |
Reviews 0
FAQ about Patients for Affordable Drugs
What has the press written about Patients for Affordable Drugs?
Parsers VC has collected 9 articles mentioning Patients for Affordable Drugs, among them “Senate's new controversial patent reform target” (May 20, 2024) and “Venture Capital Firm Shares Ambitious Value-Based Care Strategy: Buy a Health System” (Oct 9, 2023).
Is Patients for Affordable Drugs still active?
Yes, Patients for Affordable Drugs is active; its latest activity on Parsers VC dates from May 22, 2024.